A new study identified several metabolites and metabolic indicators as potential biomarkers for recurrence risk in non–muscle-invasive bladder cancer.
A large genomic analysis identified more than 60 new prostate cancer susceptibility loci, including one locus significantly associated with early onset.
An antigen-specific immunotherapeutic known as MAGE-A3 was no better than placebo for the adjuvant treatment of stage IIIB or IIIC melanoma.
In RCC patients on anti–PD-1 therapy, besides the indel count link to better OS, baseline tumor infiltration with M2 macrophages predicted improved PFS.
This is the first diagnostic classification of RCCs in patients younger than age 30 prospectively registered in a cooperative group clinical study.
In this video, Dr. Heinz Josef Lenz outlines the many advantages the development of liquid biopsy is affording cancer patients.
In women with ovarian cancer, those with early life adversity and anxiety had more dysregulation of cortisol, suggesting they may be at risk for more negative outcomes.
A phase II study found that the FGFR inhibitor erdafitinib yields a good response rate and was well tolerated in patients with urothelial carcinoma and FGFR alterations.
Dr. Hossein Borghaei discusses results of the Checkmate 227 trial and its impact on treatment decision-making in NSCLC.
The study is potentially a “leap forward” in cancer genomics, particularly for subsets of patients with metastatic and anaplastic thyroid cancer.
Treatment with the second-generation EGFR TKI dacomitinib resulted in improved overall survival over gefitinib in patients with NSCLC and activating EGFR mutations.
In the Utah Cancer Survivors Study, male thyroid cancer survivors had an almost 50% higher risk of developing cardiovascular disease than females.
A multicenter, international phase II study found higher-dose and extended-dose therapy with Ra-223 did not improve survival or pain scores.
The trastuzumab biosimilar ABP 980 showed noninferiority to trastuzumab in a large trial of patients with early HER2-positive breast cancer.
In PREOPANC, the 2-year survival rate was significantly higher for patients who received neoadjuvant chemoradiotherapy vs standard care.